• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诱导转移部位白细胞浸润介导 NGcGM3 疫苗的保护作用。

Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

机构信息

a Center of Molecular Immunology (CIM); Immunobiology Division; Atabey; Havana Cuba.

出版信息

Hum Vaccin Immunother. 2014;10(8):2312-20. doi: 10.4161/hv.29161.

DOI:10.4161/hv.29161
PMID:25424937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4896779/
Abstract

While the NGcGM3/VSSP vaccine, a preparation consisting in very small sized proteoliposomes (VSSP) obtained by the incorporation of the NGcGM3 ganglioside into the outer membrane protein (OMP) complex of Neisseria meningitides, is currently studied in late stage clinical trials in breast cancer and melanoma patients, mechanisms involved in the vaccine's antitumor effect are insufficiently understood. Here we have addressed the role of adaptive and innate immune cells in mediating the protective effect of the vaccine. To this aim we selected the 3LL-D122 Lewis lung spontaneous metastasis model. Unexpectedly, inoculation of the vaccine in tumor bearing C57BL/6 mice, either by subcutaneous (sc) or intraperitoneal (ip) routes, induced similar anti-metastatic effect. Regardless the T-independent nature of NGcGM3 ganglioside as antigen, the antimetastatic effect of NGcGM3/VSSP is dependent on CD4(+) T cells. In a further step we found that the vaccine was able to promote the increase, maturation, and cytokine secretion of conventional DCs and the maturation of Bone Marrow-derived plasmacytoid DCs. In line with this result the in vivo IFNα serum level in ip vaccinated mice increased as soon as 2h after treatment. On the other hand the infiltration of NK1.1(+)CD3(-) and NK1.1(+)CD3(+) cells in lungs of vaccinated mice was significantly increased, compared with the presence of these cells in control animal lungs. In the same way NGcGM3/VSSP mobilized acquired immunity effector cells into the lungs of vaccinated tumor bearing mice. Finally and not less noteworthy, leukocyte infiltration in lungs of tumor bearing mice correlates with vaccine induced inhibition of lung metastization.

摘要

尽管 NGcGM3/VSSP 疫苗目前正在乳腺癌和黑色素瘤患者的晚期临床试验中进行研究,该疫苗是由神经节苷脂 NGcGM3 掺入脑膜炎奈瑟氏球菌的外膜蛋白(OMP)复合物制成的非常小的脂质体(VSSP)组成的,但疫苗的抗肿瘤作用机制尚不清楚。在这里,我们研究了适应性和先天免疫细胞在介导疫苗的保护作用中的作用。为此,我们选择了 3LL-D122 Lewis 肺自发转移模型。出乎意料的是,无论是通过皮下(sc)还是腹腔内(ip)途径接种疫苗,均可在荷瘤 C57BL/6 小鼠中诱导类似的抗转移作用。尽管 NGcGM3 神经节苷脂作为抗原具有 T 细胞非依赖性,但 NGcGM3/VSSP 的抗转移作用依赖于 CD4(+)T 细胞。在进一步的步骤中,我们发现疫苗能够促进常规 DC 的增加、成熟和细胞因子分泌以及骨髓来源的浆细胞样 DC 的成熟。与这一结果一致的是,ip 接种疫苗的小鼠的 IFNα 血清水平在治疗后 2 小时内就增加了。另一方面,与对照组动物肺部相比,接种疫苗的小鼠肺部 NK1.1(+)CD3(-)和 NK1.1(+)CD3(+)细胞的浸润明显增加。同样,NGcGM3/VSSP 将获得性免疫效应细胞动员到接种疫苗的荷瘤小鼠肺部。最后,同样值得注意的是,肺部白细胞浸润与疫苗诱导的肺转移抑制相关。

相似文献

1
Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.诱导转移部位白细胞浸润介导 NGcGM3 疫苗的保护作用。
Hum Vaccin Immunother. 2014;10(8):2312-20. doi: 10.4161/hv.29161.
2
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.直接验证 NGcGM3 神经节苷脂作为癌症免疫疗法的新靶点。
Expert Opin Biol Ther. 2010 Feb;10(2):153-62. doi: 10.1517/14712590903443084.
3
Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.在临床前小鼠黑色素瘤模型中,通过GM3/VSSP疫苗围手术期免疫实现完全抗肿瘤保护。
Clin Cancer Res. 2006 Dec 1;12(23):7092-8. doi: 10.1158/1078-0432.CCR-06-1075.
4
Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3/VSSP Vaccine in Advanced Breast Cancer Patients.NGcGM3/VSSP疫苗的非乳化变体在晚期乳腺癌患者中的卓越疗效和安全性。
Breast Cancer (Auckl). 2016 Feb 18;10:5-11. doi: 10.4137/BCBCR.S32785. eCollection 2016.
5
Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides.NGcGM3/VSSP 疫苗通过抗 N-糖基化神经节苷脂过表达的转染 B16 小鼠黑色素瘤细胞的抗肿瘤保护作用。
In Vivo. 2012 Jul-Aug;26(4):609-17.
6
Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.纳米颗粒佐剂抑制肿瘤诱导的髓系来源抑制细胞功能。
J Immunol. 2011 Jan 1;186(1):264-74. doi: 10.4049/jimmunol.1001465. Epub 2010 Dec 6.
7
CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.CIGB-247:一种基于 VEGF 的治疗性疫苗,可减少 C57Bl/6 和 BALB/c 小鼠肿瘤的实验性和自发性肺转移。
Vaccine. 2012 Feb 27;30(10):1790-9. doi: 10.1016/j.vaccine.2012.01.006. Epub 2012 Jan 10.
8
Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.抗表皮生长因子受体单克隆抗体(anti-EGFR mAb)与靶向神经节苷脂NGcGM3的免疫疗法联合使用,对其抗转移作用产生协同增强效果。
Oncotarget. 2018 May 8;9(35):24069-24080. doi: 10.18632/oncotarget.25290.
9
Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.极小尺寸蛋白脂质体诱导的天然免疫细胞因子,一种源自奈瑟菌的免疫佐剂。
Clin Exp Immunol. 2007 Feb;147(2):379-88. doi: 10.1111/j.1365-2249.2006.03297.x.
10
Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).掺入超小型蛋白脂质体(VSSP)后对免疫原性较差的神经节苷脂免疫反应的增强。
Vaccine. 1999 Aug 20;18(1-2):190-7. doi: 10.1016/s0264-410x(99)00219-4.

引用本文的文献

1
Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.抗表皮生长因子受体单克隆抗体(anti-EGFR mAb)与靶向神经节苷脂NGcGM3的免疫疗法联合使用,对其抗转移作用产生协同增强效果。
Oncotarget. 2018 May 8;9(35):24069-24080. doi: 10.18632/oncotarget.25290.
2
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.表皮生长因子受体(EGFR)与N-羟乙酰神经氨酸神经节苷脂(NeuGcGM3)在癌症中频繁共表达:其潜在的治疗意义
Clin Exp Metastasis. 2016 Oct;33(7):717-25. doi: 10.1007/s10585-016-9811-0. Epub 2016 Jul 23.

本文引用的文献

1
NGcGM3/VSSP vaccine as treatment for melanoma patients.NGcGM3/VSSP 疫苗治疗黑色素瘤患者。
Hum Vaccin Immunother. 2013 Jun;9(6):1237-40. doi: 10.4161/hv.24115. Epub 2013 Feb 26.
2
Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma.皮下注射 N-糖基化 GM3/VSSP 疫苗对晚期皮肤黑色素瘤患者的疗效。
Cancer Manag Res. 2012;4:341-5. doi: 10.2147/CMAR.S22617. Epub 2012 Oct 5.
3
Plasmacytoid dendritic cells and cancer.浆细胞样树突状细胞与癌症。
J Leukoc Biol. 2011 Oct;90(4):681-90. doi: 10.1189/jlb.0411190. Epub 2011 Jul 5.
4
Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.活化的 NKT 细胞和 NK 细胞使 T 细胞抵抗髓源抑制细胞,并在 FVBN202 转基因小鼠中导致有效的过继细胞治疗乳腺癌。
J Immunol. 2011 Jul 15;187(2):708-17. doi: 10.4049/jimmunol.1100502. Epub 2011 Jun 13.
5
NGcGM3 ganglioside: a privileged target for cancer vaccines.NGcGM3神经节苷脂:癌症疫苗的优先靶点。
Clin Dev Immunol. 2010;2010:814397. doi: 10.1155/2010/814397. Epub 2010 Oct 27.
6
Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.一种基于NeuGcGM3的癌症疫苗的免疫原性和安全性:转移性乳腺癌患者对照研究的结果。
Hum Vaccin. 2010 Sep 14;6(9). doi: 10.4161/hv.6.9.12571.
7
Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance.解析浆细胞样树突状细胞在病毒感染、自身免疫和耐受中的功能。
Immunol Rev. 2010 Mar;234(1):142-62. doi: 10.1111/j.0105-2896.2009.00881.x.
8
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.直接验证 NGcGM3 神经节苷脂作为癌症免疫疗法的新靶点。
Expert Opin Biol Ther. 2010 Feb;10(2):153-62. doi: 10.1517/14712590903443084.
9
Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases.浆细胞样树突状细胞:在病毒感染和自身免疫性疾病中感知核酸
Nat Rev Immunol. 2008 Aug;8(8):594-606. doi: 10.1038/nri2358.
10
Antimicrobial peptides and self-DNA in autoimmune skin inflammation.自身免疫性皮肤炎症中的抗菌肽与自身DNA
Curr Opin Immunol. 2008 Aug;20(4):401-7. doi: 10.1016/j.coi.2008.06.008. Epub 2008 Jul 24.